Trial Condition(s):
Rosacea
A Study of Patient Concerns and Treatment Satisfaction in Patients Being Treated with Finacea Foam for Rosacea
Bayer Identifier:
19638
ClinicalTrials.gov Identifier:
EudraCT Number:
Not Available
EU CT Number:
Not Available
Study Completed
Trial Purpose
To survey rosacea patients about their concerns, treatment satisfaction, and quality of life associated with their Finacea Foam treatment
Inclusion Criteria
- At least 18 years of age - Diagnosis of rosacea by a medical professional - Currently using Finacea Foam as topical monotherapy for rosacea - Willing and able to provide voluntary, informed consent to participate in this study
Exclusion Criteria
- Use of any other topical treatment for rosacea at the time of enrollment
Trial Summary
Enrollment Goal
2200
Trial Dates
Phase
4
Could I receive a placebo?
No
Products
Finacea® (azelaic acid) Foam, 15% (Azelaic Acid, BAY39-6251)
Accepts Healthy Volunteers
No
Where to Participate
Loading...
Locations
Status
| Locations | Status | |
|---|---|---|
Locations Xcenda, LLC Palm Harbor, United States, 34685 | Status Completed | Contact Us: E-mail: [email protected] Phone: +49 30 300139003 |
Trial Design
A Study of Patient Concerns and Treatment Satisfaction in Patients Being Treated with Finacea Foam for Rosacea
Trial Type:
Observational
Intervention Type:
Drug
Trial Purpose:
N/A
Allocation:
N/A
Blinding:
N/A
Assignment:
N/A
Trial Arms:
1
Primary Outcome
- Demographics and clinical characteristicsCollected patient demographics and characteristics are : -Year of birth - Gender - Insurance typeTimeframe: one-time survey in 2 week recruitment window
- Rosacea-relevant comorbidities and complicationsPatient reported history of the following will be collected : - Blepharitis - Conjunctivitis - Corneal neovascularization/keratitis - Depression - MigraineTimeframe: one-time survey in 2 week recruitment window
- Rosacea subtypePatient reported diagnosis of the following will be collected: - Erythematotelangiectatic (facial redness) - Papulopustular (bumps and pimples) - Phymatous (enlargement of the nose) - Ocular (eye irritation) - UnknownTimeframe: one-time survey in 2 week recruitment window
- Past use of topical rosacea treatmentsPatient reported use of the following medications will be collected: - Metronidazole gel - Metronidazole cream - Metronidazole lotion - Metronidazole emulsion - Brimonidine tartrate gelTimeframe: one-time survey in 2 week recruitment window
- Patient concerns collected by Rosacea Treatment Preference QuestionnaireRosacea Treatment Preference Questionnaire is a survey to assess patient self-reported rosacea subtype and severity, and to evaluate the concerns that contribute to patient satisfaction/dissatisfaction, as well as treatment decisions with rosacea topical treatmentsTimeframe: one-time survey in 2 week recruitment window
- Treatment satisfaction assessed by Satisfaction with Medicines Questionnaire (SATMED-Q)SATMED-Q is a 17-question, validated, multidimensional generic questionnaire designed for use in patients with any chronic disease treated with medicinesTimeframe: one-time survey in 2 week recruitment window
- Quality of life measured by Dermatology Life Quality Index (DLQI)DLQI is a widely used dermatology-related quality of life toolTimeframe: one-time survey in 2 week recruitment window
Additional Information
Copyright © Bayer
Powered by
